Pancreatic islet transplantation offers a promising, minimally-invasive approach to restore normoglycemia and insulin independence in type 1 diabetics with hypoglycemic unawareness. However, its clinical applicability is compromised by the need for toxic immunosuppressive drugs, the need for islets from several pancreas donors to achieve insulin independence, and the long-term decline in islet function after transplantation. The protocols outlined in this application are multi-center, prospective, open-label trials that address these issues by assessing islet function and survival in 3 groups of patients with type 1 diabetes: 1) patients treated with a standardized steroid-free, calcineurin inhibitor sparing protocol (Clinical Islet Transplantation (CIT) protocol 07);2) patients treated with the standardized immunosuppressive protocol as well as the immunosuppressive drug deoxyspergualin (CIT protocol 03);and 3) patients with functional kidney allografts (CIT protocol 06). These protocols were originally initiated by the University of Minnesota, Northwestern University, and the University of California, San Francisco as part of the CIT consortium. Moving forward, the administration of the three will separate for logistic reasons as per NIH directive and RFA-DK-09-501, but the sites will continue to share the knowledge, expertise, and protocols that were initiated during the first five years of the CIT.

Public Health Relevance

(provided by applicant): The proposed clinical protocols outlined in this application are designed to: 1) examine the effects of peritransplant addition of the immunosuppressive agent deoxyspergualin to a standardized immunosuppressive regimen in pancreatic islet transplantation in type 1 diabetic recipients;and 2) examine the outcomes of pancreatic islet transplantation in type 1 diabetic recipients with kidney allografts. We believe that the results of these studies will improve the efficacy of islet transplantation and contribute to the transition of clinical islet transplantation from clinical research to clinical care.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1-GRB-7 (O1))
Program Officer
Arreaza-Rubin, Guillermo
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
Schools of Medicine
San Francisco
United States
Zip Code
Foster, Eric D; Bridges, Nancy D; Feurer, Irene D et al. (2018) Improved Health-Related Quality of Life in a Phase 3 Islet Transplantation Trial in Type 1 Diabetes Complicated by Severe Hypoglycemia. Diabetes Care 41:1001-1008
Hering, Bernhard J; Bridges, Nancy D; Eggerman, Thomas L et al. (2017) Comment on Harlan. Islet Transplantation for Hypoglycemia Unawareness/Severe Hypoglycemia: Caveat Emptor. Diabetes Care 2016;39:1072-1074. Diabetes Care 40:e111-e112
Ricordi, Camillo; Goldstein, Julia S; Balamurugan, A N et al. (2016) National Institutes of Health-Sponsored Clinical Islet Transplantation Consortium Phase 3 Trial: Manufacture of a Complex Cellular Product at Eight Processing Facilities. Diabetes 65:3418-3428
Hering, Bernhard J; Clarke, William R; Bridges, Nancy D et al. (2016) Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia. Diabetes Care 39:1230-40
Senior, Peter A; Bellin, Melena D; Alejandro, Rodolfo et al. (2015) Consistency of quantitative scores of hypoglycemia severity and glycemic lability and comparison with continuous glucose monitoring system measures in long-standing type 1 diabetes. Diabetes Technol Ther 17:235-42
Ahearn, Aaron J; Parekh, Justin R; Posselt, Andrew M (2015) Islet transplantation for Type 1 diabetes: where are we now? Expert Rev Clin Immunol 11:59-68
Posselt, Andrew M; Szot, Gregory L; Frassetto, Lynda A et al. (2010) Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation 90:1595-601
Posselt, A M; Bellin, M D; Tavakol, M et al. (2010) Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. Am J Transplant 10:1870-80